Development of cancer immunotherapy using dendritic cells genetically modified to express Interleukin-23

使用经过基因改造表达白介素 23 的树突状细胞开发癌症免疫疗法

• 批准号: 21791244
• 负责人: SATO Marimo
• 金额: $ 2.75万
• 依托单位: The University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21791244/
• 关键词: インターロイキン-23; 樹状細胞; アデノウィルスベクター; 癌免疫療法; 遺伝子治療; インターロイキン23; がん免疫療法

I investigated whether bone marrow- derived dendritic cells (BM-DCs) adenovirally transduced with genes encoding murine IL-23 have therapeutic benefits for antitumor immunotherapy. This strategy designed to deliver genetically modified DCs to tumor sites is associated with systemic and therapeutic antitumor immunity and could be an alternative approach to those using delivery of DCs loaded with defined tumor antigens. These results support the clinical development of IL-23 gene-modified DCs in patients with cancer.

我研究了用编码鼠 IL-23 的基因腺病毒转导的骨髓来源的树突状细胞 (BM-DC) 是否具有抗肿瘤免疫疗法的治疗益处。这种旨在将基因修饰的树突状细胞递送至肿瘤部位的策略与全身性和治疗性抗肿瘤免疫相关，并且可能是使用负载特定肿瘤抗原的树突状细胞递送的替代方法。这些结果支持IL-23基因修饰的DC在癌症患者中的临床开发。

项目成果

ホームページ等。

主页等

Antigen-specific antitumor effects of DNA vaccine are significantly enhanced with systemic administration of IL-23

全身注射 IL-23 可显着增强 DNA 疫苗的抗原特异性抗肿瘤作用

• 发表时间: 2009
• 作者: Kimiyasu Yoneyama;Marimo Sato;Masahisa Jinushi;Yuko Kitagawa;Hideaki Tahara
• 通讯作者: Hideaki Tahara

Cancer immunotherapy using monocyte-derived DCs stimulated with OK-432 and prostaglandin E_2 pulsed with gp100 epitope peptide in malignant melanoma

使用 OK-432 刺激的单核细胞衍生 DC 和 gp100 表位肽脉冲的前列腺素 E_2 进行癌症免疫疗法治疗恶性黑色素瘤

• 发表时间: 2009
• 作者: Marimo Sato;Akira Kanamoto;Masahisa Jinushi;Hisako Katano;Kimiyasu Yoneyama;Akihiko Itoh;Hideaki Tahara
• 通讯作者: Hideaki Tahara

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

• DOI: 10.1186/1479-5876-7-45
• 发表时间: 2009-06-17
• 期刊: Journal of translational medicine
• 影响因子: 7.4
• 作者: Tahara H;Sato M;Thurin M;Wang E;Butterfield LH;Disis ML;Fox BA;Lee PP;Khleif SN;Wigginton JM;Ambs S;Akutsu Y;Chaussabel D;Doki Y;Eremin O;Fridman WH;Hirohashi Y;Imai K;Jacobson J;Jinushi M;Kanamoto A;Kashani-Sabet M;Kato K;Kawakami Y;Kirkwood JM;Kleen TO;Lehmann PV;Liotta L;Lotze MT;Maio M;Malyguine A;Masucci G;Matsubara H;Mayrand-Chung S;Nakamura K;Nishikawa H;Palucka AK;Petricoin EF;Pos Z;Ribas A;Rivoltini L;Sato N;Shiku H;Slingluff CL;Streicher H;Stroncek DF;Takeuchi H;Toyota M;Wada H;Wu X;Wulfkuhle J;Yaguchi T;Zeskind B;Zhao Y;Zocca MB;Marincola FM
• 通讯作者: Marincola FM

In situ antitumor immunotherapy with blockade of MFG-E8 and chemotherapy against solid and hematological tumors

阻断 MFG-E8 的原位抗肿瘤免疫疗法和针对实体瘤和血液肿瘤的化疗

• 发表时间: 2009
• 作者: Masahisa Jinushi;Marimo Sato;Akira Kanamoto;Akihiko Itoh;Hideaki Tahara
• 通讯作者: Hideaki Tahara